<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>cerebrospinal fluid &#8211; mikrobik.net</title>
	<atom:link href="https://wp.mikrobik.net/tag/cerebrospinal-fluid/feed/" rel="self" type="application/rss+xml" />
	<link>https://wp.mikrobik.net</link>
	<description></description>
	<lastBuildDate>Wed, 25 Jun 2025 12:28:34 +0000</lastBuildDate>
	<language>tr</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.1</generator>
	<item>
		<title>Investigation of cerebrospinal fluid</title>
		<link>https://wp.mikrobik.net/investigation-of-cerebrospinal-fluid/</link>
					<comments>https://wp.mikrobik.net/investigation-of-cerebrospinal-fluid/#respond</comments>
		
		<dc:creator><![CDATA[mikrobik]]></dc:creator>
		<pubDate>Mon, 06 Feb 2012 12:13:00 +0000</pubDate>
				<category><![CDATA[Biyokimya Derlemeleri]]></category>
		<category><![CDATA[cerebrospinal fluid]]></category>
		<category><![CDATA[CSF]]></category>
		<guid isPermaLink="false"></guid>

					<description><![CDATA[NATIONAL STANDARD METHOD INVESTIGATION OF CEREBROSPINAL FLUID BSOP 27 Issued by Standards Unit, Evaluations and Standards Laboratory Centre for Infections Fulltext INDEX STATUS OF NATIONAL STANDARD METHODS&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;.. 2 INDEX&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230; 3 AMENDMENT PROCEDURE&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;.. 4...]]></description>
										<content:encoded><![CDATA[<p>NATIONAL STANDARD METHOD<br />
INVESTIGATION OF CEREBROSPINAL FLUID<br />
BSOP 27<br />
Issued by Standards Unit, Evaluations and Standards Laboratory Centre for Infections<br />
<a href="http://www.hpa-standardmethods.org.uk/documents/bsop/pdf/bsop27.pdf" target="_blank" rel="noopener">Fulltext</a></p>
<p>INDEX<br />
STATUS OF NATIONAL STANDARD METHODS&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;.. 2<br />
INDEX&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230; 3<br />
AMENDMENT PROCEDURE&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;.. 4<br />
SCOPE OF DOCUMENT &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230; 5<br />
INTRODUCTION &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;. 5<br />
TECHNICAL INFORMATION/LIMITATIONS &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230; 10<br />
1 SAFETY CONSIDERATIONS &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;. 11<br />
1.1 SPECIMEN COLLECTION &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;. 11<br />
1.2 SPECIMEN TRANSPORT AND STORAGE &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;. 11<br />
1.3 SPECIMEN PROCESSING&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;. 11<br />
2 SPECIMEN COLLECTION &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230; 12<br />
2.1 OPTIMAL TIME OF COLLECTION &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230; 12<br />
2.2 CORRECT SPECIMEN TYPE AND METHOD OF COLLECTION &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;. 12<br />
2.3 ADEQUATE QUANTITY AND APPROPRIATE NUMBER OF SPECIMENS &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230; 12<br />
3 SPECIMEN TRANSPORT AND STORAGE &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230; 12<br />
3.1 TIME BETWEEN SPECIMEN COLLECTION AND PROCESSING&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230; 12<br />
3.2 SPECIAL CONSIDERATIONS TO MINIMISE DETERIORATION &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;. 12<br />
4 SPECIMEN PROCESSING &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;.. 12<br />
4.1 TEST SELECTION &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;.. 12<br />
4.2 APPEARANCE &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;. 13<br />
4.3 MICROSCOPY&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;. 13<br />
4.4 CULTURE AND INVESTIGATION &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;. 15<br />
4.5 IDENTIFICATION &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;. 16<br />
4.6 ANTIMICROBIAL SUSCEPTIBILITY TESTING&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230; 17<br />
5 REPORTING PROCEDURE&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;. 17<br />
5.1 APPEARANCE &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;. 17<br />
5.2 MICROSCOPY&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;. 17<br />
5.3 CULTURE &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;. 18<br />
5.4  ANTIMICROBIAL SUSCEPTIBILITY TESTING &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;.. 18<br />
6 REPORTING TO THE HPA (LOCAL AND REGIONAL SERVICES AND CENTRE FOR<br />
INFECTIONS)&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;. 19<br />
7 ACKNOWLEDGEMENTS AND CONTACTS&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;.. 20<br />
APPENDIX &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;.. 21<br />
REFERENCES &#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;.. 22</p>
]]></content:encoded>
					
					<wfw:commentRss>https://wp.mikrobik.net/investigation-of-cerebrospinal-fluid/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Multiplicity of cerebrospinal fluid functions: New challenges in health and disease</title>
		<link>https://wp.mikrobik.net/multiplicity-of-cerebrospinal-fluid-functions-new-challenges-in-health-and-disease/</link>
		
		<dc:creator><![CDATA[mikrobik]]></dc:creator>
		<pubDate>Mon, 10 May 2010 13:52:00 +0000</pubDate>
				<category><![CDATA[Biyokimya Derlemeleri]]></category>
		<category><![CDATA[BOS]]></category>
		<category><![CDATA[cerebrospinal fluid]]></category>
		<category><![CDATA[CSF]]></category>
		<guid isPermaLink="false"></guid>

					<description><![CDATA[Multiplicity of cerebrospinal fluid functions: New challenges in health and disease Conrad E Johanson, John A Duncan, Petra M Klinge, Thomas Brinker, Edward G Stopa and Gerald D Silverberg Cerebrospinal Fluid Research 2008,...]]></description>
										<content:encoded><![CDATA[<p><strong><span style="color:#5C3566;">Multiplicity of cerebrospinal fluid functions: New challenges in health and disease</span></strong><br />
Conrad E Johanson, John A Duncan, Petra M Klinge, Thomas Brinker, Edward G Stopa  and Gerald D Silverberg</p>
<p><a href="http://www.cerebrospinalfluidresearch.com/content/pdf/1743-8454-5-10.pdf" target="_blank" rel="noopener">Cerebrospinal Fluid Research 2008, 5:10</a></p>
<p>This review integrates eight aspects of cerebrospinal fluid (CSF) circulatory dynamics: formation rate, pressure, flow, volume, turnover rate, composition, recycling and reabsorption. Novel ways to modulate CSF formation emanate from recent analyses of choroid plexus transcription factors (E2F5), ion transporters (NaHCO3 cotransport), transport enzymes (isoforms of carbonic anhydrase), aquaporin 1 regulation, and plasticity of receptors for fluid-regulating neuropeptides. A greater appreciation of CSF pressure (CSFP) is being generated by fresh insights on peptidergic regulatory servomechanisms, the role of dysfunctional ependyma and circumventricular organs in causing congenital hydrocephalus, and the clinical use of algorithms to delineate CSFP waveforms for diagnostic and prognostic utility. Increasing attention focuses on CSF flow: how it impacts cerebral metabolism and hemodynamics, neural stem cell progression in the subventricular zone, and catabolite/peptide clearance from the CNS. The pathophysiological significance of changes in CSF volume is assessed from the respective viewpoints of hemodynamics (choroid plexus blood flow and pulsatility), hydrodynamics (choroidal hypo- and hypersecretion) and neuroendocrine factors (i.e., coordinated regulation by atrial natriuretic peptide, arginine vasopressin and basic fibroblast growth factor). In aging, normal pressure hydrocephalus and Alzheimer&#8217;s disease, the expanding CSF space reduces the CSF turnover rate, thus compromising the CSF sink action to clear harmful metabolites (e.g., amyloid) from the CNS. Dwindling CSF dynamics greatly harms the interstitial environment of neurons. Accordingly the altered CSF composition in neurodegenerative diseases and senescence, because of adverse effects on neural processes and cognition, needs more effective clinical management. CSF recycling between subarachnoid space, brain and ventricles promotes interstitial fluid (ISF) convection with both trophic and excretory benefits. Finally, CSF reabsorption via multiple pathways (olfactory and spinal arachnoidal bulk flow) is likely complemented by fluid clearance across capillary walls (aquaporin 4) and arachnoid villi when CSFP and fluid retention are markedly elevated. A model is presented that links CSF and ISF homeostasis to coordinated fluxes of water and solutes at both the blood-CSF and blood-brain transport interfaces.</p>
<p>Outline<br />
1 Overview</p>
<p>2 CSF formation</p>
<p>2.1 Transcription factors</p>
<p>2.2 Ion transporters</p>
<p>2.3 Enzymes that modulate transport</p>
<p>2.4 Aquaporins or water channels</p>
<p>2.5 Receptors for neuropeptides</p>
<p>3 CSF pressure</p>
<p>3.1 Servomechanism regulatory hypothesis</p>
<p>3.2 Ontogeny of CSF pressure generation</p>
<p>3.3 Congenital hydrocephalus and periventricular regions</p>
<p>3.4 Brain response to elevated CSF pressure</p>
<p>3.5 Advances in measuring CSF waveforms</p>
<p>4 CSF flow</p>
<p>4.1 CSF flow and brain metabolism</p>
<p>4.2 Flow effects on fetal germinal matrix</p>
<p>4.3 Decreasing CSF flow in aging CNS</p>
<p>4.4 Refinement of non-invasive flow measurements</p>
<p>5 CSF volume</p>
<p>5.1 Hemodynamic factors</p>
<p>5.2 Hydrodynamic factors</p>
<p>5.3 Neuroendocrine factors</p>
<p>6 CSF turnover rate</p>
<p>6.1 Adverse effect of ventriculomegaly</p>
<p>6.2 Attenuated CSF sink action</p>
<p>7 CSF composition</p>
<p>7.1 Kidney-like action of CP-CSF system</p>
<p>7.2 Altered CSF biochemistry in aging and disease</p>
<p>7.3 Importance of clearance transport</p>
<p>7.4 Therapeutic manipulation of composition</p>
<p>8 CSF recycling in relation to ISF dynamics</p>
<p>8.1 CSF exchange with brain interstitium</p>
<p>8.2 Components of ISF movement in brain</p>
<p>8.3 Compromised ISF/CSF dynamics and amyloid retention</p>
<p>9 CSF reabsorption</p>
<p>9.1 Arachnoidal outflow resistance</p>
<p>9.2 Arachnoid villi vs. olfactory drainage routes</p>
<p>9.3 Fluid reabsorption along spinal nerves</p>
<p>9.4 Reabsorption across capillary aquaporin channels</p>
<p>10 Developing translationally effective models for restoring CSF balance</p>
<p>11 Conclusion</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Cerebrospinal Fluid Analysis</title>
		<link>https://wp.mikrobik.net/cerebrospinal-fluid-analysis/</link>
		
		<dc:creator><![CDATA[mikrobik]]></dc:creator>
		<pubDate>Mon, 27 Apr 2009 23:56:00 +0000</pubDate>
				<category><![CDATA[Biyokimya Derlemeleri]]></category>
		<category><![CDATA[cerebrospinal fluid]]></category>
		<guid isPermaLink="false"></guid>

					<description><![CDATA[Cerebrospinal Fluid Analysis DEAN A. SEEHUSEN, MARK M. REEVES, DEMITRI A. FOMIN Am Fam Physician 2003;68:1103-8 Lumbar puncture is frequently performed in primary care. Properly interpreted tests can make cerebrospinal fluid (CSF) a...]]></description>
										<content:encoded><![CDATA[<p><strong><span style="color:#5C3566;">Cerebrospinal Fluid Analysis </span></strong><br />
DEAN A. SEEHUSEN, MARK M. REEVES, DEMITRI A. FOMIN</p>
<p><a href="http://www.aafp.org/afp/20030915/1103.pdf" target="_blank" rel="noopener">Am Fam Physician 2003;68:1103-8</a></p>
<p>Lumbar puncture is frequently performed in primary care. Properly interpreted tests can make cerebrospinal fluid (CSF) a key tool in the diagnosis of a variety of diseases. Proper evaluation of CSF depends on knowing which tests to order, normal ranges for the patient&#8217;s age, and the test&#8217;s limitations. Protein level, opening pressure, and CSF-to-serum glucose ratio vary with age. Xanthochromia is most often caused by the presence of blood, but several other conditions should be considered. The presence of blood can be a reliable predictor of subarachnoid hemorrhage but takes several hours to develop. The three-tube method, commonly used to rule out a central nervous system hemorrhage after a &#8220;traumatic tap,&#8221; is not completely reliable. Red blood cells in CSF caused by a traumatic tap or a subarachnoid hemorrhage artificially increase the white blood cell count and protein level, thereby confounding the diagnosis. Diagnostic uncertainty can be decreased by using accepted corrective formulas. White blood cell differential may be misleading early in the course of meningitis, because more than 10 percent of cases with bacterial infection will have an initial lymphocytic predominance and viral meningitis may initially be dominated by neutrophils. Culture is the gold standard for determining the causative organism in meningitis. However, polymerase chain reaction is much faster and more sensitive in some circumstances. Latex agglutination, with high sensitivity but low specificity, may have a role in managing partially treated meningitis. To prove herpetic, cryptococcal, or tubercular infection, special staining techniques or collection methods may be required.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
